CymaBay Therapeutics (CBAY) Misses Q1 EPS by 20c

CymaBay Therapeutics (NASDAQ: CBAY) reported Q1 EPS of ($0.29), $0.20 worse than the analyst estimate of ($0.09).

For earnings history and earnings-related data on CymaBay Therapeutics (CBAY) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Investing.com’s stocks of the week
• CoStar Group acquires Zonda for $800M, adding new home data